RM-001 (Guangzhou Ruifeng)

N/A

Report date: 2025/07/28 17:40:09

Base Information

Drug NameRM-001 (Guangzhou Ruifeng)
Drug Alias NameHBG基因修饰的自体CD34+造血干细胞RM-001RM001
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionHemoglobin subunit gamma-1 gene transferenceHemoglobin subunit gamma-2 gene transference
TargetsHemoglobin subunit gamma-1Hemoglobin subunit gamma-2
Therapy Area/Indicationsbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Reforgene Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Reforgene Medicine Co Ltd
Inactive CompaniesN/A
Active Indicationsbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A